{"protocolSection":{"identificationModule":{"nctId":"NCT03341390","orgStudyIdInfo":{"id":"CV010-027"},"organization":{"fullName":"Bristol-Myers Squibb","class":"INDUSTRY"},"briefTitle":"An Investigational Study to Assess the Effect of BMS-986177 on Aspirin in Healthy Participants","officialTitle":"A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study to Evaluate the Effect of Coadministration of Multiple Doses of BMS-986177 on Aspirin in Healthy Participants"},"statusModule":{"statusVerifiedDate":"2018-01","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2017-10-18","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2017-11-16","type":"ACTUAL"},"completionDateStruct":{"date":"2017-11-16","type":"ACTUAL"},"studyFirstSubmitDate":"2017-10-30","studyFirstSubmitQcDate":"2017-11-09","studyFirstPostDateStruct":{"date":"2017-11-14","type":"ACTUAL"},"lastUpdateSubmitDate":"2018-01-17","lastUpdatePostDateStruct":{"date":"2018-01-19","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Bristol-Myers Squibb","class":"INDUSTRY"}},"oversightModule":{"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The purpose of this study is to investigate the effect of taking multiple doses of BMS-986177 when aspirin is taken once-daily. Eligible participants will receive twice-daily doses of BMS-986177 or placebo, with a once-daily dose of aspirin. The safety, tolerability and movement of BMS-986177 into, through and out of the body (pharmacokinetics/PK) will be assessed, as will the effect of BMS-986177 on the PK of aspirin."},"conditionsModule":{"conditions":["Healthy Volunteers"],"keywords":["Healthy participants","Healthy subjects","Strokes"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"BASIC_SCIENCE","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":20,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Aspirin","type":"ACTIVE_COMPARATOR","description":"325 mg tablet, once daily for 5 days (Day -5 to -1)","interventionNames":["Drug: Aspirin"]},{"label":"BMS-986177 plus aspirin","type":"EXPERIMENTAL","description":"200 mg BMS-986177 twice daily and 325 mg tablet aspirin once daily (Day 1-7)","interventionNames":["Drug: Aspirin","Drug: BMS-986177"]},{"label":"Placebo plus aspirin","type":"PLACEBO_COMPARATOR","description":"200 mg Placebo twice daily and 325 mg tablet aspirin once daily (Day 1-7)","interventionNames":["Drug: Aspirin","Drug: Placebo"]}],"interventions":[{"type":"DRUG","name":"Aspirin","description":"1 x 325 mg tablet of aspirin administered once daily","armGroupLabels":["Aspirin","BMS-986177 plus aspirin","Placebo plus aspirin"],"otherNames":["Acetylsalicylic Acid"]},{"type":"DRUG","name":"BMS-986177","description":"200 mg of BMS-986177 administered twice daily","armGroupLabels":["BMS-986177 plus aspirin"]},{"type":"DRUG","name":"Placebo","description":"200 mg of Placebo administered twice daily","armGroupLabels":["Placebo plus aspirin"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of participants with non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs) leading to discontinuation when coadministered BMS-986177 (twice daily) and aspirin (once daily)","description":"Safety and tolerability of multiple doses of BMS-986177 measured by investigator assessment","timeFrame":"Up to 10 days"},{"measure":"Number of potential clinically significant changes in electrical activity of the heart in participants coadministered BMS-986177 (twice daily) and aspirin (once daily)","description":"Measured by electrocardiogram (ECG)","timeFrame":"Up to 10 days"},{"measure":"Number of participants with vital sign abnormalities.","timeFrame":"Up to 10 days"},{"measure":"Number of participants with physical examination abnormalities.","timeFrame":"Up to 10 days"},{"measure":"Number of participants with clinical laboratory abnormalities.","timeFrame":"Up to 10 days"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Signed written consent form.\n* Healthy male and female participants (not of childbearing potential), determined by no clinically significant deviation from normal in medical history, physical examination, ECGs (electrocardiograms) and clinical laboratory determinations.\n* Women participants must have documented proof they are not of childbearing potential.\n* Males sexually active with women of childbearing potential must agree to follow instructions for method(s) of contraception for duration of treatment with BMS-986177, and for a total of 93 days after the last dose of BMS-986177; and must be willing to refrain from sperm donation during this time. Azoospermic males are exempt from contraceptive requirements.\n* Normal renal function at screening (Glomerula Filtration Rate â‰¥ 80 mL/min/1.73 m2.\n* Body Mass Index (BMI) of 18.0 kg/m2 to 32.0 kg/m2 inclusive.\n\nExclusion Criteria:\n\n* Women who are of childbearing potential or breastfeeding.\n* Any significant acute or chronic illness.\n* History of gastroesophageal reflux disease, dyspepsia, protracted nausea or chronic diarrhea.\n* History of upper gastrointestinal ulcer disease within 6 months or current symptomatic or recent gastrointestinal disease that could impact absorption of study treatment.\n* Abnormal renal profile and/or hematuria (if male) within 3 months of study start.\n* History or evidence of abnormal bleeding and/or coagulation disorder and/or evidence of coagulopathy, prolonged or unexplained clinically significant bleeding, or frequent unexplained bruising or thrombus formation, or a history of spontaneous bleeding.\n* Any major surgery within 4 weeks of study treatment administration or planned within 2 weeks after completion of the study.\n* Donation of blood to a blood bank or in a clinical study (except screening or follow-up visit) within 4 weeks of study treatment administration (within 2 weeks for plasma only).\n* Blood transfusion within 3 months of study treatment administration.\n* Use of tobacco- or nicotine-containing products (including, but not limited to cigarettes, pipes, cigars, e-cigarettes, chewing tobacco, nicotine patches, nicotine lozenges or nicotine gum) within 6 months prior to study treatment administration.\n* History of allergy to aspirin or related compounds.\n\nOther protocol-defined inclusion/exclusion criteria could apply.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"55 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Bristol-Myers Squibb","affiliation":"Bristol-Myers Squibb","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"PPD Austin Clinic","city":"Austin","state":"Texas","zip":"78744","country":"United States","geoPoint":{"lat":30.26715,"lon":-97.74306}}]},"referencesModule":{"seeAlsoLinks":[{"label":"FDA Safety Alerts and Recalls","url":"http://www.fda.gov/Safety/Recalls"}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"}]},"interventionBrowseModule":{"meshes":[{"id":"D000001241","term":"Aspirin"}],"ancestors":[{"id":"D000000894","term":"Anti-Inflammatory Agents, Non-Steroidal"},{"id":"D000018712","term":"Analgesics, Non-Narcotic"},{"id":"D000000700","term":"Analgesics"},{"id":"D000018689","term":"Sensory System Agents"},{"id":"D000018373","term":"Peripheral Nervous System Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000000893","term":"Anti-Inflammatory Agents"},{"id":"D000018501","term":"Antirheumatic Agents"},{"id":"D000005343","term":"Fibrinolytic Agents"},{"id":"D000050299","term":"Fibrin Modulating Agents"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000010975","term":"Platelet Aggregation Inhibitors"},{"id":"D000016861","term":"Cyclooxygenase Inhibitors"},{"id":"D000004791","term":"Enzyme Inhibitors"},{"id":"D000058633","term":"Antipyretics"}],"browseLeaves":[{"id":"M4238","name":"Aspirin","asFound":"Barriers","relevance":"HIGH"},{"id":"M3907","name":"Anti-Inflammatory Agents","relevance":"LOW"},{"id":"M3908","name":"Anti-Inflammatory Agents, Non-Steroidal","relevance":"LOW"},{"id":"M3722","name":"Analgesics","relevance":"LOW"},{"id":"M20476","name":"Analgesics, Non-Narcotic","relevance":"LOW"},{"id":"M20294","name":"Antirheumatic Agents","relevance":"LOW"},{"id":"M8163","name":"Fibrinolytic Agents","relevance":"LOW"},{"id":"M13555","name":"Platelet Aggregation Inhibitors","relevance":"LOW"},{"id":"M18899","name":"Cyclooxygenase Inhibitors","relevance":"LOW"},{"id":"M7641","name":"Enzyme Inhibitors","relevance":"LOW"},{"id":"M28866","name":"Antipyretics","relevance":"LOW"}],"browseBranches":[{"abbrev":"Antipy","name":"Antipyretics"},{"abbrev":"Infl","name":"Anti-Inflammatory Agents"},{"abbrev":"ARhu","name":"Antirheumatic Agents"},{"abbrev":"FiAg","name":"Fibrinolytic Agents"},{"abbrev":"Analg","name":"Analgesics"},{"abbrev":"PlAggInh","name":"Platelet Aggregation Inhibitors"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}